NASDAQ:IBRX ImmunityBio Q4 2024 Earnings Results & Report $9.80 -0.32 (-3.16%) Closing price 04:00 PM EasternExtended Trading$9.84 +0.04 (+0.41%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ImmunityBio beat analyst earnings expectations but missed on revenue in its Q4 2024 results, released March 3, 2025. The company reported EPS of -$0.15 versus the -$0.26 consensus estimate, while revenue of $7.55 million fell short of the $8.74 million estimate by $1.19 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 3, 2025TimeBefore Market OpensConference Call7:00 AM ET ImmunityBio EPS ResultsActual EPS-$0.15Consensus EPS -$0.26Beat/MissBeat by +$0.11One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersImmunityBio Revenue ResultsActual Revenue$7.55 millionExpected Revenue$8.74 millionBeat/MissMissed by -$1.19 millionYoY Revenue GrowthN/AUpcoming EarningsImmunityBio's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) ImmunityBio Q4 2024 Earnings FAQ Did ImmunityBio beat earnings estimates for Q4 2024? ImmunityBio (NASDAQ:IBRX) reported earnings of -$0.15 per share for Q4 2024, beating the consensus estimate of -$0.26. The report was announced on Monday, March 3, 2025. What was ImmunityBio's revenue for Q4 2024? ImmunityBio reported revenue of $7.55 million for Q4 2024, against a consensus estimate of $8.74 million. When is ImmunityBio's next earnings date? ImmunityBio's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for ImmunityBio on the company's earnings history page. ImmunityBio Earnings HeadlinesImmunityBio (IBRX) Could Be 33% Undervalued Following Its Ottawa Symposium UpdateOctober 8, 2026 | finance.yahoo.comImmunityBio to Participate in the Piper Sandler Virtual Oncology SymposiumOctober 8, 2026 | businesswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 13 at 1:00 AM | Stansberry Research (Ad)ImmunityBio (NASDAQ:IBRX) Stock: Insider Barry Simon Sells 25,000 SharesOctober 8, 2026 | americanbankingnews.comImmunityBio, Inc. (NASDAQ:IBRX) Stock Has Consensus Target Price of $14.20October 8, 2026 | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Stock: Insider Cheryl Cohen Sells 81,056 SharesOctober 8, 2026 | americanbankingnews.comSee More ImmunityBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email. Email Address About ImmunityBioImmunityBio (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator. In 2024, the U.S. Food and Drug Administration approved ANKTIVA in combination with Bacillus Calmette-Guérin for adults with non-muscle-invasive bladder cancer that is unresponsive to BCG and includes carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating ANKTIVA and other investigational therapies in additional cancer settings. ImmunityBio was founded by physician and entrepreneur Patrick Soon-Shiong and is headquartered in the United States. The company’s research and clinical development activities have included collaborations and trials involving patients in multiple countries. Its leadership has included Soon-Shiong as executive chairman and global chief medical officer, with Richard Adcock serving as president and chief executive officer.View ImmunityBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
